Core and Group Health

CVS' Caremark leans on biosimilars and AI to combat rising drug costs

"By tackling branded pharmas and equitable pricing strategies that have left Americans carrying the financial weight of global drug innovation, the government is helping to relieve a long-standing burden on U.S. consumers and businesses," David Joyner, the CVS chief executive officer, said.